Browse studies

Find your next paid study

192 recruiting studies matching your filters

A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).

A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of Lisaftoclax (APG-2575) combin…

Higher-risk Myelodysplastic Syndrome

Estimated

~$10 – $8,750

Ascentage Pharma Group Inc.NCT06641414

Phase 1

Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 as a monotherapy, …

Acute Myeloid LeukemiaMyelodysplastic Syndrome

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT06419634

Observational

A Prospective Study of Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS

This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physi…

Whole Genome SequencingAcute Myeloid LeukemiaMyelodysplastic Syndromes

Estimated

~$10 – $6,250

Washington University School of MedicineNCT04986657

Tissue Procurement For Hematolymphoid Conditions

RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in…

Chronic Myeloproliferative DisordersLeukemiaLymphoma+5 more

Estimated

~$10 – $750

UNC Lineberger Comprehensive Cancer CenterNCT01137643

A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1/2 Study and Treated With ARD103 CAR-T Cell Therapies

This study will evaluate the long-term safety of ARD103 cellular therapies

Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, in Relapsed or RefractoryMDS (Myelodysplastic Syndrome)

Estimated

~$10 – $1,050

ARCE Therapeutics, Inc.NCT06906380

Phase 1

A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerate…

Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in RelapseMyelodysplastic Syndrome Acute Myeloid Leukemia

Estimated

~$10 – $7,500

AB ScienceNCT05211570

Phase 1

A Phase 1 Study of BXCL701 in Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Myelodysplastic Syndrome With Excess Blasts - 2

The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or …

Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2

Estimated

~$10 – $7,500

Eric Stephen Winer, MDNCT05703542

The Prospective Collection, Storage and Reporting of Data on Patients

To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematop…

Acute Myelogenous LeukemiaAcute Lymphocytic LeukemiaChronic Myelogenous Leukemia+7 more

Estimated

~$10 – $750

Wake Forest University Health SciencesNCT01890486

Phase 1

An Open-label, Non-randomized, Prospective Trial to Evaluate the Effect of Renal Function Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics in Patients With AML or MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

This study aim is to assess, if treosulfan pharmacokinetics are influenced by declined renal function and by race/ethnicity of patients. The study also aims to…

Acute Myeloid Leukaemia (AML)Myelodysplastic Syndrome (MDS)Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Estimated

~$10 – $8,750

medac GmbHNCT05534620

Phase 1

CROSSCHECK-001: A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants …

High-risk Myelodysplastic SyndromeChronic Myelomonocytic Leukemia (CMML)AML - Acute Myeloid Leukemia+1 more

Estimated

~$10 – $8,750

Crossbow Therapeutics, Inc.NCT06994676

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical tria…

Cancer, MetastaticCancerCancer of Pancreas+40 more

Estimated

~$10 – $1,050

Massive Bio, Inc.

Defining Inflammatory Biomarkers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes

Why Is This Research Study Being Conducted? * The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are mo…

Myelodysplastic Syndromes, Adult

Estimated

~$10 – $750

University of VermontNCT06692894